# Vernalis

Vernalis is an other based in Cambridge, United Kingdom.

## Overview

- **Organization type:** other
- **Headquarters:** Cambridge, United Kingdom
- **Region:** North America
- **Address:** Granta Park, Great Abington, Cambridge CB21 6GB, United Kingdom
- **Assets under management:** Undisclosed
- **Website:** www.vernalis.com
- **LinkedIn:** https://www.linkedin.com/company/vernalis

## Regulatory record

- **Reports private funds:** No

## About

Vernalis collaborates with a wide range of organisations to enable drug discovery programs through both short- and long-term projects

## Sectors

- Healthcare Services
- Industrial Tech
- AI/ML

## Offices

- Pleasant Hill, United States
- Herzliya, Israel
- New York, United States
- Dubai, United Arab Emirates

## People

- James Murray — Head of Research
- Clare Searle — Finance Director
- Susan Wallcraft — General Counsel
- Ben Davis — Business Development
- Kerry — Business Development
- Lisa Baker — Project Leader
- James Davidson — Director of Chemistry

## Questions

### Who runs investment decisions at Vernalis?

Vernalis operates as a contract research organization, not an investment firm. Dr. James Murray serves as Head of Research, overseeing drug discovery programs. There is no investment committee or allocation function.

### How does Vernalis source its drug discovery projects?

Vernalis partners with pharmaceutical and biotechnology companies through short- and long-term collaborations, often targeting challenging therapeutic targets such as protein-protein interactions. It also benefits from its position as part of the HitGen Group, which provides access to DNA-encoded library (DEL) technology.

### Does Vernalis participate in fund commitments or only direct deals?

Vernalis does not make fund commitments or direct investments. Its business model is fee-for-service research collaborations with pharma and biotech companies.

### What investment stages does Vernalis typically target?

Vernalis does not target investment stages. It offers a full drug development pipeline from gene discovery to candidate selection, including hit identification, lead optimization, and pre-clinical studies.

### How is Vernalis related to HitGen Group?

Vernalis is part of the HitGen Group, a publicly traded company (HitGen Inc., listed on the Shanghai Stock Exchange) specializing in DNA-encoded library technology. This affiliation gives Vernalis access to HitGen's proprietary DEL platform.

## Related profiles

- [MRE Properties](https://altss.com/profile/mre-properties)
- [Guanzi Private Equity Management (Hangzhou)](https://altss.com/profile/guanzi-private-equity-management-hangzhou)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/vernalis

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology